Having trouble accessing articles? Reset your cache.

Cypress, Forest Laboratories musculoskeletal, neurology news

Cypress will restructure and reduce headcount by 123 (86%) to 20 after it discontinued co-promotion of fibromyalgia drug Savella milnacipran in the U.S. with partner Forest. The cuts come from

Read the full 301 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE